PMID- 17828291
OWN - NLM
STAT- MEDLINE
DCOM- 20080402
LR  - 20220410
IS  - 0007-1188 (Print)
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
VI  - 153
IP  - 2
DP  - 2008 Jan
TI  - The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: 
      delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
PG  - 199-215
AB  - Cannabis sativa is the source of a unique set of compounds known collectively as 
      plant cannabinoids or phytocannabinoids. This review focuses on the manner with 
      which three of these compounds, (-)-trans-delta9-tetrahydrocannabinol 
      (delta9-THC), (-)-cannabidiol (CBD) and (-)-trans-delta9-tetrahydrocannabivarin 
      (delta9-THCV), interact with cannabinoid CB1 and CB2 receptors. Delta9-THC, the 
      main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial 
      agonist and in line with classical pharmacology, the responses it elicits appear 
      to be strongly influenced both by the expression level and signalling efficiency 
      of cannabinoid receptors and by ongoing endogenous cannabinoid release. CBD 
      displays unexpectedly high potency as an antagonist of CB1/CB2 receptor agonists 
      in CB1- and CB2-expressing cells or tissues, the manner with which it interacts 
      with CB2 receptors providing a possible explanation for its ability to inhibit 
      evoked immune cell migration. Delta9-THCV behaves as a potent CB2 receptor 
      partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor 
      agonists in CB1-expressing tissues. This it does with relatively high potency and 
      in a manner that is both tissue and ligand dependent. Delta9-THCV also interacts 
      with CB1 receptors when administered in vivo, behaving either as a CB1 antagonist 
      or, at higher doses, as a CB1 receptor agonist. Brief mention is also made in 
      this review, first of the production by delta9-THC of pharmacodynamic tolerance, 
      second of current knowledge about the extent to which delta9-THC, CBD and 
      delta9-THCV interact with pharmacological targets other than CB1 or CB2 
      receptors, and third of actual and potential therapeutic applications for each of 
      these cannabinoids.
FAU - Pertwee, R G
AU  - Pertwee RG
AD  - School of Medical Sciences, Institute of Medical Sciences, University of 
      Aberdeen, Aberdeen, UK. rgp@abdn.ac.uk
LA  - eng
GR  - P01 DA009789/DA/NIDA NIH HHS/United States
GR  - R01 DA003672/DA/NIDA NIH HHS/United States
GR  - R01 DA003672-24A1/DA/NIDA NIH HHS/United States
GR  - DA-09789/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070910
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (Receptor, Cannabinoid, CB2)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 28172-17-0 (tetrahydrocannabivarin 9)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Animals
MH  - Cannabidiol/*pharmacology
MH  - Dronabinol/*analogs & derivatives/pharmacology
MH  - Drug Tolerance
MH  - Humans
MH  - Receptor, Cannabinoid, CB1/agonists/antagonists & inhibitors/*drug effects
MH  - Receptor, Cannabinoid, CB2/agonists/antagonists & inhibitors/*drug effects
MH  - Synaptic Transmission/drug effects
PMC - PMC2219532
EDAT- 2007/09/11 09:00
MHDA- 2008/04/03 09:00
PMCR- 2009/01/01
CRDT- 2007/09/11 09:00
PHST- 2007/09/11 09:00 [pubmed]
PHST- 2008/04/03 09:00 [medline]
PHST- 2007/09/11 09:00 [entrez]
PHST- 2009/01/01 00:00 [pmc-release]
AID - 0707442 [pii]
AID - 10.1038/sj.bjp.0707442 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 
      Sep 10.